These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 26980750)
1. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750 [TBL] [Abstract][Full Text] [Related]
2. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011 [TBL] [Abstract][Full Text] [Related]
3. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418 [TBL] [Abstract][Full Text] [Related]
4. Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR. Wakamatsu M; Okuno Y; Murakami N; Miwata S; Kitazawa H; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Suzuki K; Kawashima N; Nishikawa E; Narita A; Nishio N; Kojima S; Muramatsu H; Takahashi Y Leukemia; 2021 Jan; 35(1):259-263. PubMed ID: 32307441 [No Abstract] [Full Text] [Related]
5. A new player SETs in myeloid malignancy. Trimarchi T; Ntziachristos P; Aifantis I Nat Genet; 2013 Aug; 45(8):846-7. PubMed ID: 23892662 [TBL] [Abstract][Full Text] [Related]
6. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422 [No Abstract] [Full Text] [Related]
7. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965 [TBL] [Abstract][Full Text] [Related]
9. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Caye A; Rouault-Pierre K; Strullu M; Lainey E; Abarrategi A; Fenneteau O; Arfeuille C; Osman J; Cassinat B; Pereira S; Anjos-Afonso F; Currie E; Ariza-McNaughton L; Barlogis V; Dalle JH; Baruchel A; Chomienne C; Cavé H; Bonnet D Leukemia; 2020 Jun; 34(6):1658-1668. PubMed ID: 31776464 [TBL] [Abstract][Full Text] [Related]
10. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720 [TBL] [Abstract][Full Text] [Related]
13. Integrated molecular profiling of juvenile myelomonocytic leukemia. Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595 [TBL] [Abstract][Full Text] [Related]
14. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330 [TBL] [Abstract][Full Text] [Related]
15. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399 [TBL] [Abstract][Full Text] [Related]
16. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia. De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880 [TBL] [Abstract][Full Text] [Related]